A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Year: 2014
Type: conference-abstract
Abstract: Meeting abstracts Colorectal carcinoma (CRC) is the third-most commonly diagnosed cancer in the U.S., and the third-most common cause of cancer death. There were 136,830 new cases of CRC and 50,310 deaths due to CRC in 2014. For patients with unresectable metastatic disease, initial therapy
Institutions: Duke Medical Center, MacroGenics (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2002048343